Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

143results about How to "Avoid immune rejection" patented technology

Medical dressing with bioactivity and preparation method of medical dressing

The invention relates to a medical dressing with bioactivity and a preparation method of the medical dressing and belongs to the technical field of biomedical engineering and material science. The medical dressing with the bioactivity is used for covering skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repair and is prepared as follows: one or more of embryonic stem cells, umbilical cord blood stem cells, amniotic fluid stem cells, peripheral blood stem cells and bone mesenchymal stem cells of humans or animals are cultured in vitro, stem cell growth factors secreted in the logarithmic growth phase are collected and mixed in proportion with one or more of I type collagen, III type collagen, chitosan, hyaluronic acid, chondroitin sulfate and sodium alginate, thin-layer sponge is taken as an inner layer, a porous high-polymer material film outer layer prepared from a mixture formed by one or more of PLA (polylactic acid), PGA (polyglycolic acid), PLGA (poly(lactic-co-glycolic acid)) and PCL (polycaprolactone) is attached, the product is frozen-dried and cut, and the medical dressing with the bioactivity is formed and used for treating skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repairing.
Owner:南京天其美生物技术有限公司

Yeast recombinant human type I collagen alpha 1 chain protein, synthesis method and application thereof

PendingCN110964099AInefficient translationOptimize secondary structureCosmetic preparationsConnective tissue peptidesPichia pastorisYeast chromosome
The invention discloses a yeast recombinant human type I collagen alpha 1 chain protein, a synthesis method and application thereof. The recombinant human type I collagen alpha 1 chain protein of theinvention consists of an N-terminal affinity purification marker, a human type I collagen alpha 1 chain mature peptide sequence and a C-terminal affinity purification marker. The bispecific affinity purification markers designed at the two terminals are beneficial to purification of the recombinant protein and are also beneficial to detection and full-length identification of the recombinant protein. The synthesis method comprises the following steps: firstly optimizing collagen gene sequence by utilizing common codons of pichia pastoris at gene level and synthesizing the whole gene artificially, then constructing a recombinant vector through PCR, enzyme digestion, connection and the like, and integrating into yeast artificial chromosome to construct recombinant pichia pastoris engineeringbacteria for secretory expression of the recombinant human type I collagen alpha 1 chain protein. The bispecific affinity purification marker carried by the recombinant human type I collagen alpha 1chain protein of the invention can be subjected to two-step specific purification to easily obtain high-purity products.
Owner:JIANGSU TRAUTEC MEDICAL TECH CO LTD

Cervices intraepithelial neoplasia model and model establishing method

InactiveCN101125102ARich sourcesExplore the mechanism of carcinogenesisDiagnosticsSurgeryHuman tumorImmunodeficiency
The present invention relates to a cervical intraepithelial neoplasia model and the method of establishing model, which is characterized in that the cervical intraepithelial neoplasia tissue is embedded in the immunodeficiency mice to establish cervical intraepithelial neoplasia model. The method of establishing model is characterized in that the cervical intraepithelial neoplasia tissue is respectively taken from the biopsy under the vaginoscope and the tissues which are confirmed by the department of pathology and is inoculated subcutaneously in the back of the mice; the immunodeficiency mice of the present invention can overcome the xenoislet immune rejection reaction and receive the transplantation of the human tumor tissues, the tissue model after the transplantation has significant and stable character, short observation period and greater clinical reference significance of the experimental results. The present invention can explore the mechanism of the carcinogenesis of cervical carcinoma by outcome of the pathological process of CIN I, CIN II and CIN III animal models. Furthermore, by observing the period of the outcome of the cervical intraepithelial neoplasia tissue of the animal model, the present invention provides the feasible clinical animal experimental model for reversing the malignant transformation of the CIN I and CIN II lesion tissues.
Owner:ANHUI PROVINCIAL HOSPITAL

Method for generating autologous retinal stem cells and autologous retinal cells by reversely differentiating human body cells, kit and application of autologous retinal stem cells and autologous retinal cells

The invention provides a method for generating autologous retinal stem cells and autologous retinal cells by reversely differentiating human body cells. The method comprises the following steps of: culturing the human body cells in steps in a culture medium which contains different plant extracts and proteins, so that the human body cells are reversely differentiated to generate the autologous retinal stem cells and then continuously generate a plurality of autologous retinal cells. Tens of billions of a first generation of autologous retinal stem cells are generated within 2 to 3 weeks. The plant and protein-induced human autologous retinal stem cells have the same cell specific phenotype as human natural retinal stem cells and various cell differentiation abilities. The autologous retinal stem cells and the autologous retinal cells have good application prospect in the field of treating diseases, such as retinal pigment degeneration, and also have good potential application prospect in the fields of regenerative medicine and autologous tissue organ engineering. The autologous retinal stem cells and the autologous retinal cells have the possibility to be produced massively in an industrialization way.
Owner:BEIJING CSC CREATION BIOTECH

Yeast recombined human-source I-type collagen alpha1 chain protein, synthesis method and application thereof

The invention discloses yeast recombined human-source I-type collagen alpha1 chain protein, a synthesis method and an application thereof. The recombinant human-source I-type collagen alpha1 chain protein is composed of N-terminal affinity purification marker, human-source I-type collagen alpha1 chain mature peptide sequence and C-terminal affinity purification marker, and the double specific affinity purification markers are designed at two ends of the protein, so that purification of the recombinant protein is facilitated, and detection and full-length identification of the recombinant protein are facilitated. The synthesis method includes utilizing pichia pastoris idiomatic codon to optimize a collagen gene sequence and performing artificial whole-gene synthesis on a gene level; building a recombinant vector through PCR, enzyme digestion and connection, and integrating the recombinant vector into yeast chromosome to build a recombinant pichia pastoris engineered strain secreting andexpressing the recombined human-source I-type collagen alpha1 chain protein. The double specific affinity purification markers carried by the protein is supportive of two-step specific purification,and easiness in acquiring a high-purity product is realized.
Owner:JIANGSU TRAUTEC MEDICAL TECH CO LTD

Preparation and applications of biologically camouflaged targeting nano drug delivering system for treating ischemic cerebral stroke

The invention relates to preparation and applications of a biologically camouflaged targeting nano drug delivering system for treating ischemic cerebral stroke. The nano drug delivering system is compose of a drug, an inner core drug carrier, a biologically camouflaging shell, and a target finding material, wherein the drug is bilobalide B, the inner core drug carrier is recombinant high density lipoprotein, a drug is physically embedded into the drug carrier to form a drug loaded inner core; the biologically camouflaging shell is a blood platelet membrane, the drug loaded inner core is embedded in the blood platelet membrane in a co-extrusion mode to form a biomimetic drug loaded nano particle; the target finding material is a cerebral ischemia targeting peptide (CITP), and the CITP is used to modify the surface of the biomimetic drug loaded nano particle to form the biologically camouflaged targeting nano drug delivering system. Recombinant high density lipoprotein is used to wrap bilobalide B to form the drug loaded inner core, a blood platelet membrane and a blood platelet with a CITP modified surface are taken as the biomimetic shells to construct a nano particle for treatingischemic cerebral stroke, the circulation time of the nano particle in human body is prolonged, and the nano particle has a good targeting performance.
Owner:CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products